Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2280]
News [5215]
Articles [128]
Editorials [4]
Conferences [157]
elearning [13]
Novel agent CC-292 for CLL using the B-cell receptor pathway
Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
Novel agent CC-292 for CLL using the B-cell receptor pathway ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2013
Encouraging early results with GS-9973 for CLL and NHL
Dr Jeff Sharman- US Oncology, Eugene, Oregon
Encouraging early results with GS-9973 for CLL and NHL ( Dr Jeff Sharman- US Oncology, Eugene, Oregon )
18 Dec 2013
PI3K-delta inhibitor idelalisib success in CLL
Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
PI3K-delta inhibitor idelalisib success in CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2013
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for...
Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, Lille...
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for multiple myeloma ( Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, Lille, France )
18 Dec 2013
T cell immunotherapy for leukaemia in preclinical setting
Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA
T cell immunotherapy for leukaemia in preclinical setting ( Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA )
17 Dec 2013
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia...
Dr Richard Furman - New York Weill Cornell Medical Center, USA
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL) ( Dr Richard Furman - New York Weill Cornell Medical Center, USA )
17 Dec 2013
New agents in CLL
Dr Jacqueline Barrientos - LIJ Medical Center, New York, USA
New agents in CLL ( Dr Jacqueline Barrientos - LIJ Medical Center, New York, USA )
13 Dec 2013
Chronic lymphocytic leukaemia: A new treatment era is born
Dr John Gribben - Barts Cancer Institute, London, UK
Chronic lymphocytic leukaemia: A new treatment era is born ( Dr John Gribben - Barts Cancer Institute, London, UK )
13 Dec 2013
Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and...
Dr Jan Krönke - Brigham and Women's Hospital, Boston, USA
Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and IKZF3 ( Dr Jan Krönke - Brigham and Women's Hospital, Boston, USA )
8 Dec 2013
Study of the efficacy and safety of siltuximab, an anti-interleukin-6...
Dr Raymond Wong - Chinese University of Hong Kong
Study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease ( Dr Raymond Wong - Chinese University of Hong Kong )
8 Dec 2013
Results from the randomised phase III Children’s Oncology Group (COG) trial...
Dr Alan Gamis - Children’s Mercy Hospital, Kansas City, USA
Results from the randomised phase III Children’s Oncology Group (COG) trial, AAML0531 ( Dr Alan Gamis - Children’s Mercy Hospital, Kansas City, USA )
8 Dec 2013
Final stage II results of the CLL11 trial
Dr Valentin Goede - University of Cologne, Germany
Final stage II results of the CLL11 trial ( Dr Valentin Goede - University of Cologne, Germany )
8 Dec 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation